Isaac Barchas
Director at Immunome Inc. (IMNM)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $18.3M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Aug 12SEC | IMNMImmunome Inc. | Sell Plan | 10,12562,291 held (−14%) | $26.07 | $264K | -25.0% |
| Aug 12SEC | IMNMImmunome Inc. | Sell Plan | 62,291 | $26.23 | $1.6M | -25.5% |
| Aug 12SEC | IMNMImmunome Inc. | Sell Plan | 11,04892,211 held (−11%) | $27.25 | $301K | -28.3% |
| Aug 10SEC | IMNMImmunome Inc. | Sell Plan | 20,84087,664 held (−19%) | $26.06 | $543K | -25.0% |
| Aug 10SEC | IMNMImmunome Inc. | Sell Plan | 15,24872,416 held (−17%) | $26.06 | $397K | -25.0% |
| Jul 7SEC | IMNMImmunome Inc. | Sell Plan | 83,094125,410 held (−40%) | $24.11 | $2.0M | -18.9% |
| Jul 7SEC | IMNMImmunome Inc. | Sell Plan | 16,906108,504 held (−13%) | $24.20 | $409K | -19.2% |
| Jul 2SEC | IMNMImmunome Inc. | Sell Plan | 101,050308,504 held (−25%) | $21.12 | $2.1M | -7.4% |
| Jul 2SEC | IMNMImmunome Inc. | Sell Plan | 75,665232,839 held (−25%) | $22.35 | $1.7M | -12.5% |
| Jul 2SEC | IMNMImmunome Inc. | Sell Plan | 24,335208,504 held (−10%) | $23.33 | $568K | -16.2% |
| Dec 23SEC | IMNMImmunome Inc. | Sell Plan | 371,9492,042,432 held (−15%) | $21.72 | $8.1M | -10.0% |
| Dec 23SEC | IMNMImmunome Inc. | Sell Plan | 11,2512,031,181 held (−1%) | $22.34 | $251K | -12.5% |
- Sell
Director Isaac Barchas sold $264K of IMNM at $26.07 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Isaac Barchas sold $1.6M of IMNM at $26.23 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Isaac Barchas sold $301K of IMNM at $27.25 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Isaac Barchas sold $543K of IMNM at $26.06 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Isaac Barchas sold $397K of IMNM at $26.06 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Isaac Barchas sold $2.0M of IMNM at $24.11 — cuts the stake by 40%; pre-scheduled 10b5-1 plan sale.